Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that has specific diagnostic and therapeutic requirements. Currently, imaging tools show great limits to localize all residual MTC foci. Non-invasive imaging is helpful but far from perfect for guiding the re-exploration for loco regional residual MTC. The therapeutic approach is different between sporadic and hereditary MTC. In order to obtain the biochemical and anatomical control the first surgical resection is critical. Calcitonin (Ctn) rate used for MTC recurrence detection as serum marker is definite. Yet it poses a unique challenge notwithstanding its ability in detecting microscopic subclinical disease; it is not clear if patients with evident biological signs of residual MTC should be closely observed when MTC is finally found out through different investigations that localize it, or if a different aggressive approach is necessary including central neck dissection, whether or not associated with ipsilateral or bilateral lateral neck dissection. In all phases of the disease, the co-treatment by physicians with experience in MTC therapy should be sought.

Medullary thyroid cancer: strategy, pitfalls and technical aspects with emphasis on remedial surgery / O. Makay, V. Bartolo, A. Cancellieri, A. Catalfamo, F. Famà, F. Pia Pergolizzi, M. Portinari, G. Donatini, P. Carcoforo, G. Materazzi, G. Dionigi. - In: ANNALS OF THYROID. - ISSN 2522-6681. - 3:4(2018 Apr), pp. 8.1-8.11. [10.21037/aot.2018.03.02]

Medullary thyroid cancer: strategy, pitfalls and technical aspects with emphasis on remedial surgery

G. Dionigi
2018

Abstract

Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that has specific diagnostic and therapeutic requirements. Currently, imaging tools show great limits to localize all residual MTC foci. Non-invasive imaging is helpful but far from perfect for guiding the re-exploration for loco regional residual MTC. The therapeutic approach is different between sporadic and hereditary MTC. In order to obtain the biochemical and anatomical control the first surgical resection is critical. Calcitonin (Ctn) rate used for MTC recurrence detection as serum marker is definite. Yet it poses a unique challenge notwithstanding its ability in detecting microscopic subclinical disease; it is not clear if patients with evident biological signs of residual MTC should be closely observed when MTC is finally found out through different investigations that localize it, or if a different aggressive approach is necessary including central neck dissection, whether or not associated with ipsilateral or bilateral lateral neck dissection. In all phases of the disease, the co-treatment by physicians with experience in MTC therapy should be sought.
Recurrence; re-do surgery; calcitonin (Ctn); multiple endocrine neoplasia type 2 (MEN type 2); follow-up; molecular targeted therapy; thyroidectomy
Settore MED/18 - Chirurgia Generale
https://aot.amegroups.com/article/view/4169/4961
Article (author)
File in questo prodotto:
File Dimensione Formato  
aot-03-8.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 757.26 kB
Formato Adobe PDF
757.26 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/881202
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact